Short Article
Dmitry Kravchenko, N.N. Blokhi
Abstract
Breast cancer (BC) keeps being the most predominant malignant disease in women. In recent years, a trend towards“rejuvenescence” of the malady has been observed that affects its features. Despite modern methods of diagnosis and complextreatment used in young patients, survival rates in this age group are inferior that’s associated with biological and morphologicalpeculiarities of BC in young age. Gradually are being collected data according to what age might be an independent factorexacerbating prognosis. For BC patients younger 40 years, various aspects of adjuvant therapy remain ambiguous: prolongedtamoxifen use, aromatase inhibitors prescription, BRCA profiling, ovarian function suppression, a role of chemotherapy-inducedamenorrhea in prognosis, fertility and social concerns. The issue of appropriate, personalized adjuvant hormone therapy of BC iscomplex and heterogenous that requires a necessity to further conduct international randomized trials.